Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3

R. Alvarez, C. Sette, D. Yang, R. M. Eglen, R. Wilhelm, E. R. Shelton, M. Conti

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Prostaglandin E2 produces a transient increase in the intracellular concentration of cAMP in a human promonocytic cell line (U937). The temporal pattern consists of a rapid increase followed by a gradual decline to a new steady state. The decline phase coincides with an increase in the activity of a high affinity form of cAMP phosphodiesterase (PDE). Immunoprecipitation with specific antibodies revealed that the activated enzyme is a variant of PDE-4D. To confirm this observation, three isoforms of human PDE-4 (A, B, and D) were cloned and expressed in Sf9 cells with recombinant baculovirus infection. The activity of only one of the isoforms (PDE-4D3) increased after incubation with the catalytic subunit of protein kinase A and Mg-ATP. Hydrolytic activity of human PDE-4D3 was dependent on Mg2+. Before phosphorylation, the concentration-response curve for Mg2+ was biphasic and ranged from 0.1 to 100 mM. Phosphorylation of PDE-4D3 by protein kinase A produced a monophasic Mg2+ response curve (0.5 V(max) = 0.2 mM). Phosphorylation of PDE-4D3 increased the sensitivity of the enzyme to inhibition by RS-25344 (~100-fold) and RS-33793 (~330-fold). Thus, phosphorylation of PDE-4D3 induces an apparent conformation change that increases maximum velocity and sensitivity to inhibition by some analogues of nitraquazone. These observations provide the basis for a novel pharmacological strategy that targets an activated form of PDE in human leukocytes. Selective PDE-4D3 inhibitors may have useful ante inflammatory properties with fewer adverse side effects than other PDE-4 inhibitors.

Original languageEnglish
Pages (from-to)616-622
Number of pages7
JournalMolecular Pharmacology
Volume48
Issue number4
Publication statusPublished - 1995

Fingerprint

Phosphoric Diester Hydrolases
Cyclic AMP
Phosphorylation
Type 4 Cyclic Nucleotide Phosphodiesterase
Protein Isoforms
Cyclic AMP-Dependent Protein Kinase Catalytic Subunits
Phosphodiesterase 4 Inhibitors
Sf9 Cells
Phosphodiesterase Inhibitors
Baculoviridae
Enzymes
Cyclic AMP-Dependent Protein Kinases
Immunoprecipitation
Dinoprostone
Human Activities
Leukocytes
Adenosine Triphosphate
Pharmacology
Cell Line
Antibodies

ASJC Scopus subject areas

  • Pharmacology

Cite this

Alvarez, R., Sette, C., Yang, D., Eglen, R. M., Wilhelm, R., Shelton, E. R., & Conti, M. (1995). Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Molecular Pharmacology, 48(4), 616-622.

Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. / Alvarez, R.; Sette, C.; Yang, D.; Eglen, R. M.; Wilhelm, R.; Shelton, E. R.; Conti, M.

In: Molecular Pharmacology, Vol. 48, No. 4, 1995, p. 616-622.

Research output: Contribution to journalArticle

Alvarez, R, Sette, C, Yang, D, Eglen, RM, Wilhelm, R, Shelton, ER & Conti, M 1995, 'Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3', Molecular Pharmacology, vol. 48, no. 4, pp. 616-622.
Alvarez R, Sette C, Yang D, Eglen RM, Wilhelm R, Shelton ER et al. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Molecular Pharmacology. 1995;48(4):616-622.
Alvarez, R. ; Sette, C. ; Yang, D. ; Eglen, R. M. ; Wilhelm, R. ; Shelton, E. R. ; Conti, M. / Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. In: Molecular Pharmacology. 1995 ; Vol. 48, No. 4. pp. 616-622.
@article{a251ef97dd6b4436b8d66f18f2b8020f,
title = "Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3",
abstract = "Prostaglandin E2 produces a transient increase in the intracellular concentration of cAMP in a human promonocytic cell line (U937). The temporal pattern consists of a rapid increase followed by a gradual decline to a new steady state. The decline phase coincides with an increase in the activity of a high affinity form of cAMP phosphodiesterase (PDE). Immunoprecipitation with specific antibodies revealed that the activated enzyme is a variant of PDE-4D. To confirm this observation, three isoforms of human PDE-4 (A, B, and D) were cloned and expressed in Sf9 cells with recombinant baculovirus infection. The activity of only one of the isoforms (PDE-4D3) increased after incubation with the catalytic subunit of protein kinase A and Mg-ATP. Hydrolytic activity of human PDE-4D3 was dependent on Mg2+. Before phosphorylation, the concentration-response curve for Mg2+ was biphasic and ranged from 0.1 to 100 mM. Phosphorylation of PDE-4D3 by protein kinase A produced a monophasic Mg2+ response curve (0.5 V(max) = 0.2 mM). Phosphorylation of PDE-4D3 increased the sensitivity of the enzyme to inhibition by RS-25344 (~100-fold) and RS-33793 (~330-fold). Thus, phosphorylation of PDE-4D3 induces an apparent conformation change that increases maximum velocity and sensitivity to inhibition by some analogues of nitraquazone. These observations provide the basis for a novel pharmacological strategy that targets an activated form of PDE in human leukocytes. Selective PDE-4D3 inhibitors may have useful ante inflammatory properties with fewer adverse side effects than other PDE-4 inhibitors.",
author = "R. Alvarez and C. Sette and D. Yang and Eglen, {R. M.} and R. Wilhelm and Shelton, {E. R.} and M. Conti",
year = "1995",
language = "English",
volume = "48",
pages = "616--622",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3

AU - Alvarez, R.

AU - Sette, C.

AU - Yang, D.

AU - Eglen, R. M.

AU - Wilhelm, R.

AU - Shelton, E. R.

AU - Conti, M.

PY - 1995

Y1 - 1995

N2 - Prostaglandin E2 produces a transient increase in the intracellular concentration of cAMP in a human promonocytic cell line (U937). The temporal pattern consists of a rapid increase followed by a gradual decline to a new steady state. The decline phase coincides with an increase in the activity of a high affinity form of cAMP phosphodiesterase (PDE). Immunoprecipitation with specific antibodies revealed that the activated enzyme is a variant of PDE-4D. To confirm this observation, three isoforms of human PDE-4 (A, B, and D) were cloned and expressed in Sf9 cells with recombinant baculovirus infection. The activity of only one of the isoforms (PDE-4D3) increased after incubation with the catalytic subunit of protein kinase A and Mg-ATP. Hydrolytic activity of human PDE-4D3 was dependent on Mg2+. Before phosphorylation, the concentration-response curve for Mg2+ was biphasic and ranged from 0.1 to 100 mM. Phosphorylation of PDE-4D3 by protein kinase A produced a monophasic Mg2+ response curve (0.5 V(max) = 0.2 mM). Phosphorylation of PDE-4D3 increased the sensitivity of the enzyme to inhibition by RS-25344 (~100-fold) and RS-33793 (~330-fold). Thus, phosphorylation of PDE-4D3 induces an apparent conformation change that increases maximum velocity and sensitivity to inhibition by some analogues of nitraquazone. These observations provide the basis for a novel pharmacological strategy that targets an activated form of PDE in human leukocytes. Selective PDE-4D3 inhibitors may have useful ante inflammatory properties with fewer adverse side effects than other PDE-4 inhibitors.

AB - Prostaglandin E2 produces a transient increase in the intracellular concentration of cAMP in a human promonocytic cell line (U937). The temporal pattern consists of a rapid increase followed by a gradual decline to a new steady state. The decline phase coincides with an increase in the activity of a high affinity form of cAMP phosphodiesterase (PDE). Immunoprecipitation with specific antibodies revealed that the activated enzyme is a variant of PDE-4D. To confirm this observation, three isoforms of human PDE-4 (A, B, and D) were cloned and expressed in Sf9 cells with recombinant baculovirus infection. The activity of only one of the isoforms (PDE-4D3) increased after incubation with the catalytic subunit of protein kinase A and Mg-ATP. Hydrolytic activity of human PDE-4D3 was dependent on Mg2+. Before phosphorylation, the concentration-response curve for Mg2+ was biphasic and ranged from 0.1 to 100 mM. Phosphorylation of PDE-4D3 by protein kinase A produced a monophasic Mg2+ response curve (0.5 V(max) = 0.2 mM). Phosphorylation of PDE-4D3 increased the sensitivity of the enzyme to inhibition by RS-25344 (~100-fold) and RS-33793 (~330-fold). Thus, phosphorylation of PDE-4D3 induces an apparent conformation change that increases maximum velocity and sensitivity to inhibition by some analogues of nitraquazone. These observations provide the basis for a novel pharmacological strategy that targets an activated form of PDE in human leukocytes. Selective PDE-4D3 inhibitors may have useful ante inflammatory properties with fewer adverse side effects than other PDE-4 inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0028839684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028839684&partnerID=8YFLogxK

M3 - Article

C2 - 7476886

AN - SCOPUS:0028839684

VL - 48

SP - 616

EP - 622

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -